Sebastian Neggers
A5024586979- Pituitary Gland Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Childhood Cancer Survivors' Quality of Life
- Adrenal and Paraganglionic Tumors
- Acute Lymphoblastic Leukemia research
- Neuroendocrine Tumor Research Advances
- Regulation of Appetite and Obesity
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Family Support in Illness
- Palliative Care and End-of-Life Issues
- Metabolism, Diabetes, and Cancer
- Biochemical Analysis and Sensing Techniques
- Nutrition and Health in Aging
- Cancer Risks and Factors
- Cancer, Hypoxia, and Metabolism
- Diet and metabolism studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Reproductive Biology and Fertility
- Cancer survivorship and care
- Chemotherapy-induced cardiotoxicity and mitigation
- TGF-β signaling in diseases
- Adipose Tissue and Metabolism
- Pancreatic function and diabetes
- Genetic Syndromes and Imprinting
Princess Máxima Center
2016-2025
Erasmus MC
2016-2025
Erasmus University Rotterdam
2014-2024
Emma Kinderziekenhuis
2016-2022
Biotechnology Institute
2022
Ohio University
2022
Amsterdam University Medical Centers
2022
University of Amsterdam
2022
Erasmus MC - Sophia Children’s Hospital
2011-2021
Rotterdam University of Applied Sciences
2008-2021
AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated adenomas and less often sporadic cases. The clinical therapeutic features of AIPmut-associated have not been studied comprehensively.The objective the study was assess clinical/therapeutic characteristics AIPmut adenomas.This an international, multicenter, retrospective case collection/database analysis.The conducted at 36 tertiary referral endocrine genetics departments.Patients included...
Abstract Objective The aim of the Acromegaly Consensus Group was to revise and update consensus on diagnosis treatment acromegaly comorbidities last published in 2013. Participants Group, convened by 11 Steering Committee members, consisted 45 experts medical surgical management acromegaly. authors received no corporate funding or remuneration. Evidence This evidence-based developed using Grading Recommendations, Assessment, Development, Evaluation (GRADE) system describe both strength...
To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects temozolomide (TMZ) treatment.Electronic survey to ESE members Dec 2015-Nov 2016.Reports on 166 (40 PC, 125 APT, 1 unclassified) were obtained. Median age at diagnosis was 43 (range 4-79) years. 69% the clinically functioning, most frequent immunohistochemical subtype corticotroph (45%). Ki-67 index did not distinguish APT from median 7% 10%...
Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. While diagnostic and therapeutic methods have advanced, little information exists on trends in acromegaly characteristics over time. The Liège Survey (LAS) Database , relational database, designed to assess the profile of patients at diagnosis during long-term follow-up multiple treatment centers. following results were obtained diagnosis. study population consisted 3173 from ten countries; 54.5% female....
Purpose Childhood cancer survivors (CCSs) are at increased risk for subsequent malignant neoplasms (SMNs). We evaluated the long-term of SMNs in a well-characterized cohort 5-year CCSs, with particular focus on individual chemotherapeutic agents and solid risk. Methods The Dutch Cancer Oncology Group-Long-Term Effects After includes 6,165 CCSs diagnosed between 1963 2001 Netherlands. were identified by linkages Netherlands Registry, Pathology medical chart review. calculated standardized...
Despite being a classical growth disorder, pituitary gigantism has not been studied previously in standardized way. We performed retrospective, multicenter, international study to characterize large series of patients. included 208 patients (163 males; 78.4%) with hormone excess and current/previous abnormal velocity for age or final height >2 s.d. above country normal means. The median onset rapid was 13 years occurred significantly earlier females than adenomas were diagnosed males...
Abstract Purpose The 14th Acromegaly Consensus Conference was convened to consider biochemical criteria for acromegaly diagnosis and evaluation of therapeutic efficacy. Methods Fifty-six experts from 16 countries reviewed discussed current evidence focused on assays; the role imaging, pathology, clinical assessments; consequences diagnostic delay; remission recommendations follow up; value assessment monitoring in defining disease progression, selecting appropriate treatments, maximizing...
The objective of the study was to assess whether weekly administration 40 mg pegvisomant (PEG-V) improves quality life (QoL) and metabolic parameters in acromegalic patients with normal age-adjusted IGF-I concentrations during long-acting somatostatin analog (SSA) treatment.This a prospective, investigator-initiated, double blind, placebo-controlled, crossover study. Twenty subjects received either PEG-V or placebo for two consecutive treatment periods 16 wk, separated by washout period 4...
X-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by microduplications on chromosome Xq26.3, encompassing the gene GPR101, which highly upregulated in tumors. We conducted this study to explore clinical, radiological, and hormonal phenotype responses therapy patients with X-LAG syndrome. The included 18 (13 sporadic) microduplication Xq26.3. All sporadic cases had unique duplications inheritance pattern two families was dominant, all Xq26.3 duplication carriers...
Background: We previously reported the efficacy of a combined treatment active acromegaly with both long-acting somatostatin analogs (SSA) and pegvisomant (PEG-V).
Somatostatin receptor subtype 2 (sst2A) protein expression has been demonstrated to positively correlate with somatostatin analog treatment outcome in GH-secreting adenomas. Recently, a new rabbit monoclonal anti-sst2A antibody (clone UMB-1) validated as reliable method selectively detect sst2A levels formalin-fixed tissues. The aim of the study was establish whether evaluation levels, assessed routine reproducible immunohistochemistry protocol using UMB-1 antibody, may predict successful...
Treatment for acromegaly patients with long-acting somatotropin release-inhibiting factor (LA-SRIF) often does not result in complete normalization of IGF-1. Addition pegvisomant (PEGV), a GH receptor antagonist, could improve this; however, the literature has described long-term follow-up. To assess efficacy and safety this combined treatment largest current single-center cohort patients, from 2004–2013. Acromegaly were treated at least 6 months high-dose LA-SRIF. persistently elevated...
Studies investigating long-term health conditions in patients with craniopharyngioma are limited by short follow-up durations and generally do not compare effects according to initial treatment approach. In addition, studies comparing between childhood- adult-onset report conflicting results. The objective of this study was analyse a full spectrum approach age group at presentation.Cross-sectional based on retrospective data.We studied single-centre cohort 128 treated from 1980 onwards (63...
Background Heart failure is one of the most important late effects after treatment for cancer in childhood. The goals this study were to evaluate risk heart failure, temporal changes by periods, and factors childhood survivors ( CCS ). Methods Results DCOG‐LATER (Dutch Childhood Oncology Group–Long‐Term Effects After Cancer) cohort includes 6,165 5‐year diagnosed between 1963 2002. Details on prior diagnosis collected nationwide cohort. Cause‐specific cumulative incidences obtained. Cardiac...
GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze relationship between signal intensity diagnostic and hormonal tumoral responses somatostatin analogs (SSA) as primary monotherapy. Acromegaly receiving SSA for at least 3 months were included study. Hormonal, clinical general assessments performed assessed centrally. 120 acromegaly. At...
Childhood cancer survivors face late health problems; despite advances in research, details on risk remain unclear. We describe the methodological aspects of Dutch Cancer Survivor Study (DCCSS) cross-sectional clinical study (LATER 2 study).From multi-center DCCSS LATER cohort 6165 five-year diagnosed during 1963-2001, we invited 4735 eligible 2016, as well siblings and parents survivors. Gaps evidence identified development surveillance guidelines were translated into research questions for...
This review intends to provide the reader with a practical overview of several (patho)physiological conditions in which knowledge interplay between growth hormone (GH), insulin-like factor-1 (IGF-1), and insulin is important. might help treating physicians making right decisions on how intervene improve metabolism for benefit patients, understand why responds their specific cases. We will specifically address GH, IGF-1, type 1 2 diabetes mellitus, liver cirrhosis, acromegaly as examples this...
Abstract Background Because the occurrence of metabolic syndrome (MetS) might contribute to childhood cancer survivor’s excess risk cardiovascular disease, authors assessed prevalence and determinants MetS in Dutch Childhood Cancer Survivor Study (DCCSS‐LATER2) cohort. Methods In total, 2338 adult survivors (CCS) were cross‐sectionally for MetS, using Lifelines cohort ( N = 132,226 adults without a history cancer) as references. The was clinically existing classifications, well an...